Kamada Ltd
kamada.comWhat Do They Do?
Sells specialty plasma-derived medicines for rare and serious conditions to wholesalers, distributors and healthcare providers, and distributes licensed medicines in Israel.
20-F for FY2025, filed Mar 11, 2026We are a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in…View ↗
First, organic growth of our commercial portfolio, including continued investment in the commercialization and life cycle management of our…View ↗
The Proprietary Products segment includes our specialty plasma therapies product portfolio, which is comprised of six FDA-approved…View ↗
In the Distribution segment, we leverage our expertise and presence in the Israeli biopharmaceutical and healthcare market to distribute in…View ↗
Who Are Their Customers?
In the U.S., wholesalers and local distributors buy several medicines directly; elsewhere, strategic partners and local distributors handle sales of proprietary products. Israeli health plans and hospitals buy products directly or through a logistics partner.
20-F for FY2025, filed Mar 11, 2026We distribute our Proprietary Products in more than 30 countries worldwide, including the United States, Argentina, Canada, Israel, Russia…View ↗
We distribute CYTOGAM, WINRHO SDF, VARIZIG and HEPAGAM B in the U.S. market directly to wholesalers and local distributors, through our…View ↗
In the Israeli market, we currently sell and distribute GLASSIA and KAMRAB independently to local HMOs and medical centers, or through a…View ↗
Our primary customers in the Distribution segment in Israel are HMOs, including Clalit Health Services and Maccabi Healthcare Services…View ↗
How Are They Changing?
Biosimilar distribution
The Israeli distribution business has moved from preparing a biosimilar portfolio for future launch to selling biosimilar medicines.
20-F for FY2022, filed Mar 15, 2023 20-F for FY2025, filed Mar 11, 2026Our Distribution segment is comprised of sales in Israel of pharmaceutical products manufactured by third parties. Sales generated by our…View ↗
As part of our Distribution segment, we have licensed a portfolio of biosimilar products from multiple international companies for…View ↗
Who Do They Compete With?
Competes with CSL Behring, Grifols, Kedrion, ADMA, Sanofi Pasteur, BPL, Takeda, LFB, Sanofi, Beam Therapeutics, Wave Therapeutics, AlveoGene, Regeneron/Tessera Thrapeutics, Biotest, Merck, Roche, Pfizer, Gilead Sciences, and Octapharma
20-F for FY2025, filed Mar 11, 2026There are a limited number of direct competitors for each of our products in the Proprietary Products segment. These competitors include…View ↗
Loading...
